Dr. Reddy’s to bring Takeda’s QDENGA dengue vaccine to India’s private market in H1 2027
Dr. Reddy’s Laboratories will promote and distribute Takeda’s two-dose QDENGA dengue vaccine in India’s private market, subject to local regulatory procedures. CDSCO authorization covers people aged 4–60; Takeda will retain public-market distribution, product liability, and medical and brand oversight.
What happened
Dr. Reddy’s Laboratories · Dr. Reddy’s will promote and distribute Takeda’s QDENGA dengue vaccine in India’s private market, targeting a first-half 2027 launch.
Key facts
- QDENGA is expected to be available in India in the first half of 2027
- CDSCO marketing authorization covers people aged 4 to 60
- Marketing authorization was received in July 2026
- Reported dengue cases have increased 11-fold over two decades
- QDENGA has approval in 43 countries
- More than 32 million doses have been distributed globally
- The vaccine targets four dengue serotypes, DENV-1 to DENV-4
- The vaccine is administered in two doses, three months apart
- The clinical programme involved more than 60,000 people across eight dengue-endemic countries
Why this matters
The deal shows Takeda using a local commercial partner to expand private-market access while retaining public distribution, medical governance, and brand control—an attractive template for specialty healthcare collaborations in India.